<p>Lumark contains the radioactive compound lutetium (<sup>177</sup>Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example, the site of a tumour.</p><p>Lumark is to be used to radiolabel medicines that have been specifically developed for use with lutetium (<sup>177</sup>Lu) chloride.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Lumark is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.</p></div>
Therapeutic Area (MeSH)
ATC Code
V10
ATC Item
N/A
Pharmacotherapeutic Group
Therapeutic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lutetium (177Lu) chloride | N/A | lutetium (177Lu) chloride |
EMA Name
Lumark
Medicine Name
Lumark
Aliases
N/ANo risk management plan link.
